Medicine
Sodium phosphate, dibasic, and Sodium phosphate, monobasic, 0.398 g/1.105 g tablet
Sodium phosphate, dibasic, and Sodium phosphate, monobasic, 0.398 g/1.105 g tablet is a generic prescription medicine for oral use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
Key facts
- Active ingredient (INN)
- Sodium phosphate, dibasic, and Sodium phosphate, monobasic,
- Brand
- Sold under the generic name
- Strength
- 0.398 g/1.105 g
- Dosage form
- Tablet
- Route
- Oral
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 January 2012
- Identifiers
- DailyMed set ID e2fcc382-6fac-4438-ad02-ebc8528dd59aNDC 43386-030Application ANDA079247
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
No pack sizes are recorded. Pack size and quantity are confirmed on the quote.
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 10 May 1983 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Sodium phosphate, dibasic, and Sodium phosphate, monobasic,
Clinical summary
Sodium phosphate, dibasic, and Sodium phosphate, monobasic, is a fixed-dose combination medicine indicated as a source of phosphorus, for addition to large volume intravenous fluids, among other approved uses. MedsAcross supplies Sodium phosphate, dibasic, and Sodium phosphate, monobasic, for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Sodium phosphate, dibasic, and Sodium phosphate, monobasic,For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Sodium Phosphates prescribing information (Hospira) · U.S. National Library of Medicine, DailyMed
Need Sodium phosphate, dibasic, and Sodium phosphate, monobasic, 0.398 g/1.105 g tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.